2016 American Transplant Congress
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.
A large percentage of patients with end stage renal disease are known to be Hepatitis B virus (HBV) positive. A 2015 consensus guideline on use…2016 American Transplant Congress
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.
IntroductionThe purpose of this study was to evaluate the incidence of post-transplant hepatitis B (HBV) reactivation in patients who have previously cleared hepatitis B surface…2016 American Transplant Congress
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?
Background Hepatitis B virus(HBV) infection is common among uremia patients in China. Many patients received kidney transplantation are occult HBV carriers with HBsAg(-) and HBcAb(+)…2016 American Transplant Congress
The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation.
Aim: We evaluated the incidence, risk factors and clinical course of liver transplanted pediatric patients with de novo hepatitis B infection and the clinical course…2016 American Transplant Congress
Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.
Introduction: Liver transplantation for chronic hepatitis B virus (HBV) is associated with a high recurrence rate of HBV post-transplant without the use of prophylaxis. The…2016 American Transplant Congress
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan.
Background:End-stage liver disease secondary to HBV and HCV coinfection is not uncommon in Asia.However,long term outcome of such patients after living donor liver transplantation (LDLT)…2016 American Transplant Congress
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.
IntroductionThe hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Donors with Isolated Anti-HBc (“HBcAb Only”) Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb.
Use of organs from donors positive for hepatitis B virus (HBV) markers may safely expand the donor pool. Recently the American Society of Transplantation expert…2015 American Transplant Congress
Incidence of Hepatitis B Virus Reactivation in Kidney Transplant Patients Who Received Rituximab Administration
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
OBJECTIVE:The efficacy of antiviral prophylaxis for rituximab (RIT)-associated hepatitis B virus (HBV) reactivation in patients with lymphoma has been recently reported. However, the immunological effect…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »